logo
welcome
Reuters

Reuters

Moderna expects up to $3.5B in 2025 sales

Reuters
Summary
Nutrition label

81% Informative

New product launches would drive an average annual growth rate of 25% in revenue between 2026 and 2028 .

Shares of Moderna were down 7% at $ 73.94 in premarket trading.

Company last month projected sales of $3 billion and $3.5 billion for this year .

Company has been banking on revenue from newer mRNA shots, including its RSV vaccine mRESVIA.

VR Score

92

Informative language

97

Neutral language

83

Article tone

formal

Language

English

Language complexity

46

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links